Telehealth for Addiction Treatment: How Remote Care Is Expanding Access

Remote Prescribing of Addiction Medication Is Now Standard

Telehealth for addiction treatment has moved from a pandemic-era workaround to an established standard of care. In 2025, federal regulations allow doctors to prescribe buprenorphine for opioid use disorder through video calls and audio-only phone visits without requiring an initial in-person evaluation. This single policy change has expanded access to treatment for millions of Americans.

The DEA extended temporary telehealth prescribing flexibilities through December 31, 2026. Practitioners with DEA registration now prescribe Schedule III through V controlled medications, including buprenorphine, through audio-only telemedicine for opioid use disorder. This affects people in rural communities, those without reliable transportation, and anyone who faces stigma-related barriers to in-person treatment.

How Telehealth Treatment Works Today

• Doctors prescribe buprenorphine through video or audio-only telemedicine visits
• No initial in-person evaluation is required under current DEA extensions
• Opioid Treatment Programs (OTPs) permanently allow telehealth for buprenorphine initiation
• The TREATS Act, reintroduced in March 2025, aims to make these flexibilities permanent
• Research shows remote care matches in-person treatment outcomes for retention and overdose reduction

The Evidence Shows Telehealth Works

Studies from the National Institutes of Health confirm that remote addiction treatment produces results comparable to in-person care. Treatment retention rates, overdose prevention outcomes, and patient satisfaction scores are similar across both modalities.

For many patients, telehealth removes the biggest barrier to treatment: access. A person living 90 minutes from the nearest buprenorphine provider no longer needs to make that drive every week. A parent caring for young children does not need to arrange childcare. A person with physical disabilities avoids the logistical challenges of getting to a clinic.

“Telehealth for buprenorphine treatment has demonstrated effectiveness in improving treatment initiation and retention, reducing overdose rates, and enhancing overall access to care.” — Cornell University Addiction Medicine Research, 2025

New Federal Regulations for 2025

Two final rules published on January 17, 2025, outline the path toward permanent telehealth flexibilities for addiction treatment.

• Initial prescribing: Practitioners will prescribe an initial six-month supply of buprenorphine through audio-only telemedicine after reviewing the patient’s Prescription Drug Monitoring Program (PDMP) data
• Subsequent visits: After six months, patients will need either an in-person visit or another form of telemedicine for continued prescriptions
• OTP rules: Opioid Treatment Programs permanently use telehealth, including audio-only communication, to start buprenorphine treatment

The effective date of these permanent rules was postponed to December 31, 2025, following a regulatory review. The temporary flexibilities remain in place through 2026 to prevent any gap in access.

Challenges That Remain

Telehealth expansion is not without obstacles. Some pharmacists question filling prescriptions from telehealth-only visits. Interstate licensing requirements create complications for providers serving patients across state lines. Not all patients have reliable internet access or a private space for video appointments.

Insurance reimbursement for telehealth addiction treatment varies by state and plan. Some insurers reimburse telehealth visits at lower rates than in-person appointments, creating a financial disincentive for providers.

Finding Telehealth Addiction Treatment

If you need treatment for opioid use disorder, telehealth offers a direct path to care. Many treatment centers now offer virtual appointments as a standard option. Ask your provider about telehealth availability, or contact a treatment helpline to find providers who offer remote buprenorphine prescribing in your state. Treatment should be as accessible as the substances it addresses.